LEADER 04362nam  22007215  450 
001 9910300168003321
005 20200706080428.0
010   $a3-319-22542-1
024 7 $a10.1007/978-3-319-22542-5
035   $a(CKB)3710000000494183
035   $a(EBL)4068117
035   $a(SSID)ssj0001585308
035   $a(PQKBManifestationID)16264913
035   $a(PQKBTitleCode)TC0001585308
035   $a(PQKBWorkID)14864172
035   $a(PQKB)11241520
035   $a(DE-He213)978-3-319-22542-5
035   $a(MiAaPQ)EBC4068117
035   $z(PPN)258851902
035   $a(PPN)190532602
035   $a(EXLCZ)993710000000494183
100   $a20151022d2015      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aMedullary Thyroid Carcinoma $eBiology ? Management ? Treatment /$fedited by Friedhelm Raue
205   $a1st ed. 2015.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015.
215   $a1 online resource (254 p.)
225 1 $aRecent Results in Cancer Research,$x0080-0015 ;$v204
300   $aDescription based upon print version of record.
311   $a3-319-22541-3 
320   $aIncludes bibliographical references at the end of each chapters.
327   $aThyroid C-Cell Biology and Oncogenic Transformation -- Histopathology of C cells and medullary thyroid carcinoma -- Epidemiology and clinical presentation of Medullary Thyroid Carcinoma -- Medullary thyroid carcinoma: Imaging -- Calcitonin as a Biomarker for Medullary Thyroid Carcinoma -- Hereditary Medullary Thyroid Cancer, Genotype phenotype correlation -- Pheochromocytomas in Multiple Endocrine Neoplasia 2 -- Primary hyperparathyroidism in Multiple Endocrine Neoplasia 2 Syndrome -- Surgical treatment of  medullary thyroid carcinoma -- Long term follow up in medullary thyroid carcinoma -- Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
330   $aThis book offers a comprehensive overview of medullary thyroid carcinoma, both in the more common sporadic form and in the familial form, multiple endocrine neoplasia (MEN) types 2A and 2B. The coverage includes, but is not limited to, molecular biology and genetics, pathology, clinical presentation, imaging techniques, surgical treatment, and follow-up. The role of calcitonin as a highly sensitive and specific tumor marker for the screening, diagnosis, and follow-up of MTC and metastatic disease is described, and the significance of other tumor markers is also considered. With regard to treatment, the use of thyroidectomy is fully discussed, including in children carrying the mutations in the RET proto-oncogene considered causative for MEN 2. Additionally, the value of tyrosine kinase inhibitors as the most effective treatment modality in patients with a large tumor burden or rapid tumor growth, or both, is explained. Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2 will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.
410  0$aRecent Results in Cancer Research,$x0080-0015 ;$v204
606   $aOncology  
606   $aEndocrinology 
606   $aHuman genetics
606   $aNuclear medicine
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aEndocrinology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33053
606   $aHuman Genetics$3https://scigraph.springernature.com/ontologies/product-market-codes/B12008
606   $aNuclear Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H29048
615  0$aOncology  .
615  0$aEndocrinology .
615  0$aHuman genetics.
615  0$aNuclear medicine.
615 14$aOncology.
615 24$aEndocrinology.
615 24$aHuman Genetics.
615 24$aNuclear Medicine.
676   $a616.99444
702   $aRaue$b Friedhelm$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910300168003321
996   $aMedullary Thyroid Carcinoma$92535778
997   $aUNINA